Sponsor
Peking University Cancer Hospital & Institute
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Peking University Cancer Hospital & Institute appears in 119 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesNCT07848243 · lead sponsor · 2026-02-01
RECRUITINGA Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line TreatmentNCT07413042 · lead sponsor · 2026-01-20
RECRUITINGA Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical SurgeryNCT06674252 · lead sponsor · 2025-06-13
RECRUITINGA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · lead sponsor · 2025-05-15
RECRUITINGSacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationNCT06991790 · lead sponsor · 2025-05-01
RECRUITINGPhase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI FailureNCT07087223 · lead sponsor · 2025-04-08
RECRUITINGTrop-2 Targeted PET Probes in Advanced TNBCNCT07046455 · lead sponsor · 2025-03-01
RECRUITINGImmunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLCNCT06849167 · lead sponsor · 2025-03-01
RECRUITINGPrediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsyNCT06869239 · lead sponsor · 2025-02-25
RECRUITINGAssessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT06768307 · lead sponsor · 2025-01-07
RECRUITINGAl18F-HER2-BCH PET in Breast Patients Treated With ADC TherapyNCT06909604 · lead sponsor · 2025-01-01
RECRUITINGEstablishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingNCT06715020 · lead sponsor · 2024-12-10
RECRUITINGSafety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerNCT06926179 · lead sponsor · 2024-12-01
RECRUITINGRadiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung LesionsNCT06648317 · lead sponsor · 2024-11-21
RECRUITINGEvaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World StudyNCT07251868 · lead sponsor · 2024-08-01
RECRUITINGA Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT05104788 · lead sponsor · 2021-10-25
RECRUITINGSLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary NodesNCT07791771 · lead sponsor · 2026-07-31
NOT_YET_RECRUITINGAdebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNCT07567326 · lead sponsor · 2026-07-01
NOT_YET_RECRUITING5T4 Targeting Nanobody Probe for PET Imaging in Solid TumorsNCT07589101 · lead sponsor · 2026-06-01
NOT_YET_RECRUITING68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid TumorsNCT07639801 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGAbemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant TherapyNCT07599137 · lead sponsor · 2026-05-30
NOT_YET_RECRUITINGFirmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNCT07622706 · lead sponsor · 2026-05-30
NOT_YET_RECRUITINGOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNCT07527806 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGPyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNCT07470203 · lead sponsor · 2026-03-31
NOT_YET_RECRUITINGSHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNCT07417241 · lead sponsor · 2026-03-31
NOT_YET_RECRUITINGAdebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT AloneNCT07381543 · lead sponsor · 2026-03-01
NOT_YET_RECRUITINGHand and Foot Bath for Taxane-Induced Peripheral NeurotoxicityNCT07344974 · lead sponsor · 2026-02-01
NOT_YET_RECRUITINGPD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNCT07442292 · lead sponsor · 2026-02-01
NOT_YET_RECRUITINGExploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNCT07357532 · lead sponsor · 2026-01-31
NOT_YET_RECRUITINGFirmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNCT07298148 · lead sponsor · 2026-01-01
NOT_YET_RECRUITINGIvonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung CancerNCT07241819 · lead sponsor · 2025-11-30
NOT_YET_RECRUITINGMonarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATSNCT07177924 · lead sponsor · 2025-10-10
NOT_YET_RECRUITINGHigh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNCT07182708 · lead sponsor · 2025-10-01
NOT_YET_RECRUITINGA Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNCT07177950 · lead sponsor · 2025-09-30
NOT_YET_RECRUITINGAdebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLCNCT07200154 · lead sponsor · 2025-09-30
NOT_YET_RECRUITINGComparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen PathologyNCT07029646 · lead sponsor · 2025-07-01
NOT_YET_RECRUITINGEfficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung CancerNCT07004712 · lead sponsor · 2025-06-01
NOT_YET_RECRUITINGAdebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung CancerNCT06784206 · lead sponsor · 2025-02-01
NOT_YET_RECRUITINGAdjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDNCT06780839 · lead sponsor · 2025-01-15
NOT_YET_RECRUITINGReal-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLCNCT06690541 · lead sponsor · 2024-11-10
NOT_YET_RECRUITINGthe Beijing Randomized Study Of Prostate Cancer ScreeningNCT05961514 · lead sponsor · 2023-10-31
UNKNOWNClinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05955209 · lead sponsor · 2023-08-01
UNKNOWNReal-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerNCT07018427 · lead sponsor · 2023-05-01
ACTIVE_NOT_RECRUITINGComputation Prediction of Drug Response Based on Omics DataNCT05833802 · lead sponsor · 2023-02-15
UNKNOWNSignificance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung CancerNCT06081777 · lead sponsor · 2022-11-25
UNKNOWNTrastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast CancerNCT05577442 · lead sponsor · 2022-10-20
UNKNOWNA Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerNCT05380024 · lead sponsor · 2022-08-17
UNKNOWNPD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid TumorNCT05803746 · lead sponsor · 2022-07-15
UNKNOWNTislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsNCT05758116 · lead sponsor · 2022-07-07
COMPLETEDMolecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical SignificanceNCT05933863 · lead sponsor · 2022-03-29
COMPLETEDPalbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCNCT05969184 · lead sponsor · 2021-12-12
COMPLETEDPD-L1 Targeting Nanobody Probe for PET Imaging of Solid TumorNCT05156515 · lead sponsor · 2021-12-09
UNKNOWNEnsatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung CancerNCT05132218 · lead sponsor · 2021-10-19
UNKNOWNTrastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With TrastuzumabNCT05188495 · lead sponsor · 2021-05-10
UNKNOWNNiraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsNCT04764084 · lead sponsor · 2021-04-01
UNKNOWNEvaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLCNCT04629027 · lead sponsor · 2021-03-03
UNKNOWNEfficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung CancerNCT04137588 · lead sponsor · 2021-03-03
UNKNOWN[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer PatientsNCT04693169 · lead sponsor · 2021-01-15
UNKNOWNPSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate CancerNCT04560725 · lead sponsor · 2020-10-22
UNKNOWNCamrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCNCT04303130 · lead sponsor · 2019-12-31
UNKNOWNDrugs studied in this sponsor's trials
24 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Peking University Cancer Hospital & Institute as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
fluorodeoxyglucose F184
carboplatin3
gefitinib3
bevacizumab2
choline C-112
cisplatin2
dexamethasone2
ensartinib2
fluorodeoxyglucose F18 RxCUI 1362737 · Lead sponsor in 4 linked trial(s) · 2 currently recruiting
4 trials
carboplatin RxCUI 40048 · Lead sponsor in 3 linked trial(s) · 2 currently recruiting
3 trials
gefitinib RxCUI 328134 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
3 trials
bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
2 trials
choline C-11 RxCUI 1425419 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
cisplatin RxCUI 2555 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting
2 trials
dexamethasone RxCUI 3264 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
2 trials
ensartinib RxCUI 2712546 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
2 trials
etoposide RxCUI 4179 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
2 trials
pemetrexed RxCUI 68446 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting
2 trials
pertuzumab RxCUI 1298944 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
tislelizumab RxCUI 2677426 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
bevacizumab Injection RxCUI 1657065 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
everolimus RxCUI 141704 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
1 trial
goserelin RxCUI 50610 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
1 trial
lorlatinib 100 MG RxCUI 2103176 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
niraparib RxCUI 1918231 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
nivolumab RxCUI 1597876 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
sorafenib RxCUI 495881 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
1 trial
Sponsor roles
lead sponsor79
collaborator40
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.